» Articles » PMID: 15355860

Susceptibility to Neoplastic and Non-neoplastic Pulmonary Diseases in Mice: Genetic Similarities

Overview
Authors
Affiliations
Soon will be listed here.
Abstract

Chronic inflammation predisposes toward many types of cancer. Chronic bronchitis and asthma, for example, heighten the risk of lung cancer. Exactly which inflammatory mediators (e.g., oxidant species and growth factors) and lung wound repair processes (e.g., proangiogenic factors) enhance pulmonary neoplastic development is not clear. One approach to uncover the most relevant biochemical and physiological pathways is to identify genes underlying susceptibilities to inflammation and to cancer development at the same anatomic site. Mice develop lung adenocarcinomas similar in histology, molecular characteristics, and histogenesis to this most common human lung cancer subtype. Over two dozen loci, called Pas or pulmonary adenoma susceptibility, Par or pulmonary adenoma resistance, and Sluc or susceptibility to lung cancer genes, regulate differential lung tumor susceptibility among inbred mouse strains as assigned by QTL (quantitative trait locus) mapping. Chromosomal sites that determine responsiveness to proinflammatory pneumotoxicants such as ozone (O3), particulates, and hyperoxia have also been mapped in mice. For example, susceptibility QTLs have been identified on chromosomes 17 and 11 for O3-induced inflammation (Inf1, Inf2), O3-induced acute lung injury (Aliq3, Aliq1), and sulfate-associated particulates. Sites within the human and mouse genomes for asthma and COPD phenotypes have also been delineated. It is of great interest that several susceptibility loci for mouse lung neoplasia also contain susceptibility genes for toxicant-induced lung injury and inflammation and are homologous to several human asthma loci. These QTLs are described herein, candidate genes are suggested within these sites, and experimental evidence that inflammation enhances lung tumor development is provided.

Citing Articles

Dysregulation of Gap Junction Function and Cytokine Production in Response to Non-Genotoxic Polycyclic Aromatic Hydrocarbons in an In Vitro Lung Cell Model.

Romo D, Velmurugan K, Upham B, Dwyer-Nield L, Bauer A Cancers (Basel). 2019; 11(4).

PMID: 31018556 PMC: 6521202. DOI: 10.3390/cancers11040572.


Chemoprevention of Preclinical Breast and Lung Cancer with the Bromodomain Inhibitor I-BET 762.

Zhang D, Leal A, Carapellucci S, Zydeck K, Sporn M, Liby K Cancer Prev Res (Phila). 2017; 11(3):143-156.

PMID: 29246957 PMC: 10265586. DOI: 10.1158/1940-6207.CAPR-17-0264.


Differential innate immune cell signatures and effects regulated by toll-like receptor 4 during murine lung tumor promotion.

Alexander C, Xiong K, Velmurugan K, Xiong J, Osgood R, Bauer A Exp Lung Res. 2016; 42(3):154-73.

PMID: 27093379 PMC: 5506691. DOI: 10.3109/01902148.2016.1164263.


Epiregulin is required for lung tumor promotion in a murine two-stage carcinogenesis model.

Bauer A, Velmurugan K, Xiong K, Alexander C, Xiong J, Brooks R Mol Carcinog. 2016; 56(1):94-105.

PMID: 26894620 PMC: 5575741. DOI: 10.1002/mc.22475.


Bronchoalveolar Lavage Fluid Utilized Ex Vivo to Validate In Vivo Findings: Inhibition of Gap Junction Activity in Lung Tumor Promotion is Toll-Like Receptor 4-Dependent.

Hill 3rd T, Osgood R, Velmurugan K, Alexander C, Upham B, Bauer A J Mol Biomark Diagn. 2014; 5(1).

PMID: 25035812 PMC: 4098145. DOI: 10.4172/2155-9929.1000160.